Climb Bio (CLYM) announced the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Altschuller served as the Chief Financial Officer of Cerevel Therapeutics until its $8.7B acquisition by AbbVie (ABBV) and Chief Financial Officer of ImmunoGen
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM:
- Climb Bio price target raised to $8 from $7 at BTIG
- Climb Bio Unveils Promising Preclinical Data for CLYM116
- Climb Bio announces CLYM116 preclinical data
- Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity
- Climb Bio: Strong Clinical Execution and Promising Pipeline Make It a Compelling Investment Opportunity